In 2011, the National Institute for Health and Care Excellence (NICE) revised their guidance on the 10 timing of intravenous prophylactic antibiotic administration for Caesarean section, advising that 11 antibiotics should be given prior to skin incision (1) . This change has recently been supported by a 12
Cochrane review which advises administration of antibiotics 60 minutes prior to incision to prevent 13 maternal postpartum infectious morbidity (2) . While it is clearly important that women giving birth 14 are protected from infection-related complications of Caesarean section, it is also of concern that 15 nearly 25% of births in the United Kingdom (UK) delivered by Caesarean section will be affected by 16 this recommendation, which will lead to some 175,000 infants (3) annually being exposed to broad 17 spectrum antibiotics around the time of birth. NICE recommends the use of prophylactic broad 18 spectrum antibiotics for women undergoing Caesarean section which are effective against the 19 microorganisms associated with endometritis, urinary tract and wound infections (1) . These antibiotics 20 rapidly cross the placenta and will reach the baby's circulation before birth, with an inevitable but 21 not yet fully characterised influence on newborn microbial colonisation. Previous NICE guidance 22 advised cord clamping prior to giving mothers antibiotics to prevent such collateral neonatal 23 antibiotic exposure (4) . 24 25 There is increasing evidence for a functional role of gut microbiota in driving immune development 26 in the newborn and the development of chronic conditions later in life (5) . We know that the immune 27 system both modifies and is modified by our response to pathogens according to the composition of 28 early microbial colonisation (6) , and that the pattern of gut colonisation by microorganisms is 29 associated with mode of delivery (7) . There is also evidence that infants with abnormal microbiota are 30 at increased risk of diseases such as atopic dermatitis, inflammatory bowel disease and Type 1 31 diabetes (8, 9) . As such, there is growing awareness of the importance of microbes and the immune 32 system as aetiological agents in human disease (5, 10) . suggesting an adverse effect of early antibiotic exposure on the infant gut currently comes from 51 observational studies (5) , but the limitations in such studies mean they are less likely to be included in 52 systematic reviews, upon which NICE guidance is primarily based. The focus on RCTs risks potentially 53 important long-term infant health outcomes being ignored. 54
55
It is possible to test whether early life exposure to antibiotics affects microbial colonisation of the 56 gut and other mucosal surfaces in the neonate, and to explore whether antibiotics exposure might 57 lead to selective survival of microbes with genes conferring antimicrobial resistance, without RCT-58 level evidence (10) . Given that the new guidance will affect such large numbers of infants, we feel it is 59 important to consider the emerging literature on the role of the microbiota in determining long-terminfant health. This is part of a wider issue for evidence-based practice whereby high-quality reviews 61 currently prioritise evidence from studies with strong epidemiological designs, which may only 62 measure short-term outcomes, over weaker evidence of health consequences that may occur in the 63 longer term. We acknowledge that there is not yet clear evidence on which to base immediate 64 changes to clinical practice. Instead, we suggest a more nuanced weighing of evidence is needed, 65 which gives consideration to study designs capable of assessing long-term outcomes. It might also be 66 time to update how these reviews are communicated to patients, making clear where certain short-67 term gains are given precedence in structured reviews over uncertain long-term, and potentially 68 adverse, health outcomes. 69 70
